Chairman and CEO of Penumbra Inc (30-Year Financial, Insider Trades) Adam Elsesser (insider trades) sold 8,000 shares of PEN on 10/11/2019 at an average price of $146.06 a share. The total sale was $1.2 million.
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures. Penumbra Inc has a market cap of $5.11 billion; its shares were traded at around $146.89 with a P/E ratio of 489.65 and P/S ratio of 10.97. GuruFocus has detected 2 severe warning signs with Penumbra Inc. .
CEO Recent Trades:
- Chairman and CEO Adam Elsesser sold 8,000 shares of PEN stock on 10/11/2019 at the average price of $146.06. The price of the stock has increased by 0.57% since.
Directors and Officers Recent Trades:
- Director Harpreet Grewal sold 237 shares of PEN stock on 10/01/2019 at the average price of $134.93. The price of the stock has increased by 8.86% since.
- Director Thomas Wilder sold 118 shares of PEN stock on 10/01/2019 at the average price of $134.93. The price of the stock has increased by 8.86% since.
- President, International James Robert Pray sold 658 shares of PEN stock on 09/16/2019 at the average price of $150. The price of the stock has decreased by 2.07% since.
For the complete insider trading history of PEN, click here
.
